The European Commission (EC) has approved Bristol-Myers Squibb’s Opdivo (nivolumab)in combination with the company’s Yervoy (ipilimumab) for the treatment of advanced (unresectable or metastatic) melanoma in adults. This approval allows for the marketing of the Opdivo + Yervoy regimen composed of the two immunotherapies in all 28 member states of the European Union.

Opdivo is approved in several cancer indications. It is approved as a single agent for treating patients with BRAF V600 wild-type unresectable or metastatic melanoma. It is also indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. It is also approved to treat metastatic non-small cell lung cancer and for advanced renal cell carand fcinoma (RCC) who have received prior anti-angiogenic therapy.

In the US, it is also approved in combination with Bristol-Myers Squibb’s Yervoy (ipilimumab) for treating patients with unresectable or metastatic melanoma.

Source: Bristol-Myers Squibb